

Bernhard Gerber

La Stráda dal Grópp· CH-6574 Vira, SWITZERLAND
phone +41 91 811 81 86 - email bernhard.gerber@eoc.ch

PERSONAL INFORMATION

Date of birth: 21st November 1972
Place of birth: Bern, Switzerland
Citizenship: swiss and italian
Marital status: married to Giorgia Valsesia Gerber, Gambarogno TI
Languages: german (native), italian (fluent), english (fluent), french (ok)

EDUCATION

2019 *Venia legendi* University of Zürich
2001 MD Thesis
1995-2000 University of Bern, Medical School; Doctor of Medicine November 29th 2000
1993-1995 University of Zurich, Medical School
1991 Matura Track E (Economics)
1987-1991 High School Baden

PROFESSIONAL EXPERIENCE

2015-today Clinic of Hematology, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona
Deputy Head Physician. Co-founder of the *Centro di Emofilia Ticino*, and of the *Gruppo Coagulazione Ticino*
2009-2015 University Hospital Zurich, Division of Hematology (Prof. M.G.Manz). *Consultant* since 2011
2013 Founder of the *Amyloidosis Network Zurich and of the Amyloidosis Registry*. 2014-2015
Coordinator *Hämato-Onkologisches Tumorzentrum Zürich*
2008-2009 Kantonsspital Aarau, Intern, Division of Cardiology (Dr.A.Vuilliamenet)
2007-2008 Stadtspital Triemli Zurich, *Consultant*, Division of Internal Medicine (Prof. C. A. Meier)
2006 University Hospital Zurich, Intern, Intensive Care Unit (Prof. M. Maggiorini)
2005-2006 University Hospital Zurich, Intern, Division of Hematology (PD Dr. U. Schanz)
2004-2005 University Hospital Zurich, Intern, Division of Internal Medicine (Prof. A. Schaffner)
2002-2004 SZB Hospital Biel-Bienne, Intern, Division of Internal Medicine (Prof. A. U. Gerber)
2001-2002 SRO Hospital Langenthal, Intern, Division of Surgery (Dr. K. Hänni)

PROFESSIONAL QUALIFICATIONS

2020-2021 Registered for: Systemisches Management im Gesundheitswesen (CAS-HSG) 2020/2021
2015-2016 Corso LEO EOC
2013-2014 Leadership I and Leadership II USZ, Zürich
2012 Specialist for laboratory Haematology (FAMH)
2012 Specialist for Haematology (FMH)
2009 GCP 1, 2 and 3 (refresher 2012, 2014 and 2019)
2006 Specialist for General Internal Medicine (FMH)

TEACHING ACTIVITY

2020-today Medical Master School USI Teaching Modul 'Circulating cells and signaling'
2016-today Cofounder Symposium for Residents in Internal Medicine - *Innere Medizin in Lavin*
2015-today LyFE and ESO courses (Certificate in Lymphoma)
2011-today Master thesis students, UZH Zürich and USI Lugano
2015-2021 Centro professionale sociosanitario medico-tecnico Locarno - laboratory technicians
2013-2015 FMH preparatory courses for the final examination in internal medicine USZ
2011-2015 Responsible for the continuing education of trainees in hematology, USZ, Zürich
2010-2014 Careum Zürich, School for laboratory technicians

2007-2015 Medical students bedside teaching, USZ /Triemlisipital Zürich

RESEARCH EXPERIENCE (MULTICENTER TRIALS)

2020 Principal investigator OVID Trial (Steering Committee)
2020 Principal investigator IOSI-EMA-009
2020 Co-Investigator IOSI-EMA-007
2019 Co-investigator TORADI-HIT study
2019 Co-investigator IOSI-EMA-003
2018 Co-investigator IOSI-EMA-001
2018 Principal investigator IOSI-EMA-002
2018 Co-investigator CLL13
2017 Co-Investigator M15-550 (Venetoclax in CLL)
2016 Co-Investigator HOVON 135
2016 Co-Investigator GRAALL 2014
2015 Co-Investigator CML V (Tiger)
2015 Co-Investigator HOVON 132
2015 Co-Investigator SAKK 33/14
2014 Co-Investigator Chronic Lymphocytic Leukemia with 17p deletion (GS-US-312-0133)
2014 Co-Investigator CLL14 study
2014 Co-Investigator PF-05280586 vs Rituximab 1st line follicular lymphoma
2014 Principal Investigator TRC112121 (Eltrombopag in MDS)
2014 Co-Investigator MK-5592 P069 study
2014 Co-Investigator Millenium Trial
2014 Principal Investigator SAKK 39/19 Fortune study
2013 Co-Investigator Amgen EPO study
2013 Principal Investigator Telesto study
2012 Co-Investigator EMN02 HOVON/SAKK95
2011 Principal Investigator AmbiGuard
2011 Co-Investigator HOVON 103
2011 Principal Investigator PNH M07-001
2010 Co-Investigator CAMN107EIC01 (Nilotinib, Novartis)
2010 Co-Investigator CLL-11
2009 Co-Investigator LBH589 (Panobinostat, Novartis)
1999-2000 Research Associate University of Bern, Department of Transfusion Medicine

AWARDS and GRANTS

2019 Unrestricted research grant from Pfizer (60'000 CHF), co-applicant
2016 Research grant from ABREOC Bellinzona (60'000 CHF), main applicant
2014 Research grant from Krebsliga Zürich (20'000 CHF), co-applicant
2012 Research grant from Transfusion SRC Switzerland (30'000 CHF), main applicant
2000 Award for the best performance at the Medical School, University of Bern

PROFESSIONAL MEMBERSHIPS

Working Party Haemostasis Switzerland
SAKK member of the 'Lymphoma' and the 'Leukemia' working groups
Swiss Association of Residents and Consultants (VSAO)
Swiss Medical Association (FMH)
Swiss Hematology Association (SGH)
German Society of Thrombosis and Haemostasis (GTH)
International Myeloma Society (IMS)
Swiss Haemophilia Foundation
International Society of Amyloidosis

RESEARCH PROJECTS

Supportive care in haematological diseases; Amyloidosis and Plasma cell diseases; Thrombosis and Haemostasis

PUBLICATION LIST (December 2021)

ORIGINAL RESEARCH

Gerber B, Tinguely C, Bovin NV, Rieben R, Nydegger UE.

Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Gal α 1-3Gal antibodies from human serum.

Xenotransplantation 2001; 8: 106-114.

Impact: 3.484 (2018)

Vettore S, De Rocco D, **Gerber B**, Scandellari R, Bianco AM, Balduini CL, Pecci A, Fabris F, Savoia A.

A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect.

Eur J Med Genet. 2010 Sep-Oct;53(5):256-60.

Impact: 2.368 (2019)

Gerber B*, Berger MD*, Arn K, Senn O, Schanz U, Stussi G. Significant reduction of red blood cell transfusion requirements by changing from double- to single-unit transfusion policy in patients receiving intensive chemotherapies or stem cell transplantation. Haematologica. 2012 January; 97(1): 116–122.

Impact: 7.116 (2019) *equal contribution

Gerber B, Stussi G, Rosemann T, Senn O.

The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey.

BMC Cardiovascular Disorders 2012, 12:12 (29 February 2012).

Impact: 2.078 (2019)

Gerber B, Guggenberger R, Fasler D, Nair G, Manz MG, Stussi G, Schanz U.

Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole.

Blood. 2012 Sep 20;120(12):2390-4.

Impact: 17.543 (2019)

Marek A, Stern M, Chalandon Y, Ansari M, Ozsahin H, Güngör T, **Gerber B**, Kühne T, Passweg JR, Gratwohl A, Tichelli A, Seger R, Schanz U, Halter J, Stussi G.

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic stem cell transplantation.

Bone Marrow Transplantation 2014 Jan;49(1):55-61

Impact: 4.725 (2019)

Pecci A, Klersy C, Gresele P, Lee K, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier A, Fabris F, Beggiano E, Kahr WHA, Pujol-Moix N, Platokouki H, Matthijs G, Noris P, Yerram P, Hermans C, **Gerber B**, Batzios S, De Groot M, Zieger B, De Candia E, Fraticelli V, Kersseboom R, Piccoli GB, Zimmermann S, Zaninetti C, Nicchia E, Baronci C, Seri M, Knight PJ, Balduini CL, Savoia A.

MYH9-related disease: A novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.

Human Mutation 2014 Feb;35(2):236-47

Impact: 4.124 (2019)

Gerber B, Köppel J, Paul M, Thi Dan Linh Nguyen-Kim, Frauenfelder T, Nair G, Schanz U, Manz MG.

Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: A real-world, retrospective comparative single-center study.

Swiss Medical Weekly 2014 Jul 23;144:w13985.

Impact: 1.52 (2019)

Gemuenden C, Benz R, Senn O, Goede JS, Manz MG, **Gerber B**.

Efficacy of Azacitidine in de Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.

Clinical Lymphoma Myeloma & Leukemia 2015 Dec;15(12):811-5

Impact: 2.298 (2019)

Djalali S, **Gerber B**, Meli D, Senn O.

Anticoagulation control in Swiss primary care: Time in therapeutic range percentages exceed benchmarks of phase III trials.

Clinical and Applied Thrombosis/Hemostasis 2017 Sep;23(6):685-695.

Impact: 1.374 (2019)

Gerber B*, Alberio L*, Rochat S, Stenner F, Manz MG, Buser A, Schanz U, Stussi G.

Safety and Efficacy of Cryopreserved Autologous Platelet Concentrates in HLA Alloimmunized Patients with Hematological Malignancies.

Transfusion 2016 Oct;56(10):2426-2437.

Impact 2.8 (2019) *equal contribution

Bonadies N, Feller A, Rovo A, Ruefer A, Blum S, **Gerber B**, Stuessi G, Benz R, Cantoni N, Holbro A, Schmidt A, Lehmann T, Wilk M, Arndt V, the NICER Working Group* and the Swiss MDS Study Group*

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland between 2001 and 2012.

Cancer Epidemiology 2017 Feb;46:85-92

Impact: 2.179 (2019)

Strickler N, Balabanov S, Casauro K, Schanz U, Manz MG, **Gerber B**.

Acute Central Nervous System Complications and Ammonium Levels in adult Patients with Acute Lymphoblastic Leukemia receiving L-asparaginase.

Leuk Lymphoma 2018 Apr;59(4):855-862.

Impact: 2.969 (2019)

Cohn CS, Dumont LJ, Lozano M, Marks DC, Johnson L, Ismay S, Bondar N, T'Sas F, Yokoyama APH, Kutner JM, Acker JP, Bohonek M, Sailliol A, Martinaud C, Pogłód R, Antoniewicz-Papis J, Lachert E, Pun PBL, Lu J, Cid J, Guijarro F, Puig L, **Gerber B**, Alberio L, Schanz U, Buser A, Noorman F, Zoodsma M, van der Meer PF, de Korte D, Wagner S, O'Neill M.

Vox Sanguinis International Forum on platelet cryopreservation. Vox Sang. 2017 Oct;112(7):e69-e85

Impact: 2.347 (2019)

Widmer F, Balabanov S, Soldini D, Samaras P, **Gerber B**, Manz MG, Goede JS.

R-Hyper-CVAD versus R-CHOP / Cytarabine with high-dose therapy and autologous hematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.

Annals of Hematology, 2018 Feb;97(2):277-287

Impact: 2.904 (2019)

Rothenbühler S, Held U, Manz MG, Schanz U, **Gerber B**.

Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukemia.

Hematological Oncology, 2018 Apr;36(2):471-480

Impact: 2.832 (2019)

Spina V, Bruscazzin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, **Gerber B**, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.

Blood. 2018 May 31;131(22):2413-2425

Impact: 17.543 (2019)

Gerber B*, Manzoni M*, Spina V, Bruscazzin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Haematologica. February 2018: haematol.2017.184358; Doi:10.3324/haematol.2017.184358

Impact: 7.116 (2019) *equal contribution

Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, Scharl M, Samaras P*, **Gerber B***.

Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.

Leuk Lymphoma. 2018 Aug 21:1-11.

Impact: 2.969 (2019) *equal contribution

Kuster S, Stampf S, **Gerber B**, Baettig V, Weisser M, Gerull S, Medinger M, Passweg J, Schanz U, Garzoni C, Berger C, Chalandon Y, Mueller NJ, van Delden C, Neofytos D, Khanna N.

Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation: A Swiss Transplant Cohort Study.

Transpl Infect Dis. 2018 Aug 25:e12981. doi: 10.1111/tid.12981. [Epub ahead of print]

Impact: 2.071 (2019)

Ghilardi G, Pabst T, Jeker B, Müller R, Airolì A, Müller AMS, Bargetzi M, Hitz F, Baldomero H, Hei m D, SCmidt A, Rossi D, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg JR, Stussi G, Kleber M, **Gerber B**. Melphalan dose in myeloma patients ≥ 65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.

Bone Marrow Transplant. 2019 Jul;54(7):1029-1037

Impact: 4.725 (2019)

Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer A, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stussi G, Ghilardi G, **Gerber B**.

Daratumumab for Relapsed or Refractory AL Amyloidosis with high Plasma Cell Burden.

Hematological Oncology. 2019. Sep 5. doi: 10.1002/hon.2677.

Impact: 2.832 (2019)

Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscazzin A, Wu W, Moia R, Bianchi E, **Gerber B**, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.

Blood. 2020 Apr 8:blood.2019003453.

Impact: 17.543 (2019)

Kessler C, Stricker H, Demundo D, Elzi L, Monotti R, Bianchi G, Llamas M, Spinedi L, Rossi D, Chiesa AF, Pagnamenta A, Conti M, Casso G, Stoirà E, Valenti E, Colucci G, Stussi G, Previsdomini M*, **Gerber B***

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

J Thromb Thrombolysis. 2020 Aug 14;1-4. doi: 10.1007/s11239-020-02244-y. Online ahead of print. *equal contribution

Impact: 2.054 (2019)

Bruscazzin A, Terzi di Bergamo L, Spina V, Hodgkinson B, Forestieri G, Bonfiglio F, Condoluci A, Wu W, Piroso MC, Faderl MR, Koch R, Schaffer M, Alvarez JD, Fourneau N, **Gerber B**, Stussi G, Zucca E, Balasubramanian S, Rossi D. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

Blood Adv 2021 Sep 9;bloodadvances.2021004528.

Impact: 4.644 (2019)

Willekens G, Studt JD, Mendez A, Alberio L, Fontana P, Willemin WA, Schmidt A, Graf L, **Gerber B**, Bovet C, Sauter TC, Nagler M.

A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: development, diagnostic accuracy, and external validation.

Br J Haematol 2021

Impact: 5.518 (2019)

Cittone MG, Battegay R, Condoluci A, Terzi di Bergamo L, Fernandes E, Galfetti E, Noseda R, Leuppi-Taegtmeyer A, Drexler B, Ceschi A, Tsakiris DA, Berger CT, Favre G, Martin T, Korte W, Graf L, Martinez M, **Gerber B**.
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination.
J Thromb Haemost 2021 Sep;19(9):2360-2362.
Impact: 4.157 (2019)

Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini R, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, **Gerber B**, Ghia P, Gillessen S, Gomes da Silva M, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Graham Oscier E, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo' L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zaja F, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D.
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma
Blood
Impact: 17.543 (2019)

Chiesa A, Previsdomini M, Valenti E, Stora E, Stricker H, **Gerber B**, Demundo D, Clivio L, Pagnamenta A.
Prevalence and risk factors for venous thromboembolic events in critically ill patients with SARS-CoV-2 infection: a prospective observational study
Minerva Anestesiologica
Impact: 3.051 (2019)

Ruberti A, Kremer Hovinga JA, Nappi F, Vettese A, Bianchi E, Fernandes E, Galfetti E, Monotti R, Paul P, Regazzoni S, Valente D, Rossi D, Stussi G, **Gerber B**
Acquired Hemophilia A in Southern Switzerland from 2013 to 2019: A Case Series.
SMW
Impact: 1.52 (2019)

Zampiccola E, Barthelme J, Kreysing L, Nägele MP, Nebunua D, Novruzova E, Haidera T, von Eckardstein A, **Gerber B**, Schwotzer R, Ruschitzka F, Sudano I, Flammer AJ
Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis
ESC Heart Failure
Impact: 4.411 (2020)

CASE REPORTS

Gerber B, Nair G, Stussi G.
Erythroblastic Islands.
Br J Haematol. 2010 Sep;150(5):499.

Gerber B, Manser C, Wiesli P, Meier C.
A family with diabetes and heart failure.
BMJ Case Reports 2010; doi:10.1136/bcr.01.2010.2613.

Gerber B, Kyburz T, Reinhart WH, Bonetti PO, Stussi G.
Complement inhibition to treat myocardial infarction?.
BMJ Case Reports 2011;10.1136/bcr.01.2011.3701.

Gerber B, Stussi G.
Reversibility of Spur Cell Anemia.
Blood. 2011 Oct 20;118(16):4304.

Gerber B, Studt JD, Manz MG, Nair G.

Waschbärenaugen.
Schweiz Med Forum 2012;12(37):718–719.

Wolfensberger A, Benz R, Russi EW, Tinguely M, Keller C, **Gerber B**.
Husten, Atemnot und B-Symptome bei einer 40-jährigen Frau.
Internist 2013.

Benz R, **Gerber B**.
Lots of Clots and Rods.
Br J Haematol. 2014.

Schöpf Z, Marbet U, Marques Maggio E, Petrausch U, Samaras P, Schanz U, **Gerber B**, Arn K, Jung H, Müllhaupt B.
Die Hepatitis beim Morbus Crohn.
Schweiz Med Forum 2015.

Steffanoni S, **Gerber B**, Lerch E.
Gammopatia monoclonale IgM e non solo...
Tribuna medica 2017.

Lerch E, Paul P, **Gerber B**.
Meningiosi plasmacellulare nell'ambito di una leucemia plasmacellulare secondaria – un decorso raro di mieloma multiplo.
Tribuna medica 2017.

Ghilardi G, Stussi G, Mazzucchelli L, Röcken C, Rossi D, **Gerber B**.
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
Amyloid 2019

Condoluci A, Alberio L, Gomez FJ, Studt JD, Orlando C, Jochmans K, **Gerber B**.
Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation.
Thromb Res 2021

REVIEWS and CONSENSUS STATEMENTS

Gerber B, Schanz U, Stussi G.
Autoimmune hemolytic anemia.
Ther Umsch. 2010 May;67(5):229-36.

Gerber B, Senn O.
Modern risk assessment and stroke prevention in atrial fibrillation.
Praxis (Bern 1994). 2011 Sep 21;100(19):1161-72.

Gemünden C, **Gerber B**.
Polycythemia vera.
Praxis (Bern 1994). 2012 May 9;101(10):631-41.

Ellegast J, Gerber B, Manz MG.
Diagnose und Therapie der akuten myeloischen Leukämie. Schw Med Forum. 2013;13(6):112-119.

Krause H, Manz MG, **Gerber B**.
Myelodysplastisches Syndrom: Pathophysiologie, Diagnostik und Therapie.
Schw Med Forum. 2013;13(27–28):548–557.

Rauch PJ, Müllhaupt B, Biedermann L, Manz MG, Ruschitzka F, Flammer A, Segerer St, Mohebbi N, Jung HH, Moch H, Ikenberg K, Aguzzi A, Nuvolone M, Distler O, Rauch A, Fehr T, **Gerber B**.
Systemische Amyloidosen.
Schw Med Forum. 2015.

Gerber B.

Plasmazellmyelom: gute Zusammenarbeit aller Beteiligten hilft.
Praxis. 2015; 104(10):489-90.

Fuchs I, **Gerber B**, Samaras P.

Monoklonale Gammopathie in der hausärztlichen Praxis: diagnostische Abklärung und Therapie des Plasmazell-Myeloms.

Praxis. 2015; 104 (21): 1141 – 115.

Gerber B, Samaras P.

Zeitgemässe Abklärung und Therapie des Plasmazellmyeloms.

Info Onkologie & Hämatologie 01/2016.

Schwotzer R, **Gerber B**.

Die Leichtketten(AL)-Amyloidose ist nicht einfach ein Myelom - Besonderheiten der Pathophysiologie, Diagnostik und Therapie.

Leading Opinions Haematologie und Onkologie. 2016.

Benz R, Stussi G, **Gerber B**.

Paroxysmale nächtliche Hämoglobinurie.

Schw Med Forum. 2016.

Rossi D, **Gerber B**, Stussi G.

Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.

Leuk Lymphoma. 2016), DOI: 10.1080/10428194.2016.1250264.

Stussi G, **Gerber B**.

Akute myeloische Leukämie bei älteren Patienten.

Schweizer Zeitschrift für Onkologie 2016.

Gerber B.

Autologe Transplantation beim Multiplen Myelom – Der frühe Vogel fängt den Wurm.

Schweizerisches Krebsbulletin 2018.

Schwotzer R, Flammer A, **Gerber B**.

Therapie der AL Amyloidose.

Leading Opinions 2018.

Brouwer S, Laptseva N, **Gerber B**, Schotzer R, Ruschitzka F, Flammer AJ.

Cardiac amyloidosis.

Cardiovascular Medicine 2018;21(11):282–289

Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, **Gerber B**, Graf L, Hegemann I, Korte W, Kremer Hovinga J, Lecompte T, Martinez M, Nagler M, Studt JD, Tsakiris D, Wuillemin W, Asmis L.

Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 - A Swiss Consensus Statement by the Working Party Hemostasis.

Swiss Med Wkly. 2020 Apr 11;150:w20247.

Impact: 1.52 (2019)

Barco S, Bingisser R, Colucci G, Frenk A, **Gerber B**, Held U, Mach F, Mazzolai L, Righini M, Rosemann T, Sebastian T, Spescha R, Stortecky S, Windecker S, Kucher N.

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.

Trials 2020 Sep 9;21(1):770.

Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M^f, Bacher U, Bode P, Cavalli A, Condoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil AP, Pfister O, Planchette AL, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, **Gerber B**

Expert Recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-Amyloidosis
Swiss Med Wkly. 2020 Dec 5;150:w20364. doi: 10.4414/smw.2020.20364. eCollection 2020 Nov 30.
Impact: 1.52 (2019)

Fontana P, Alberio L, Albisetti M, Angelillo-Scherrer A, Asmis LM, Casini A, **Gerber B**, Graf L, Hegemann I, Korte W, Martinez M, Studt JD, Tsakiris DA, Wuillemin WA, Kremer Hovinga JA.

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors and treated with emicizumab. A consensus statement of the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network

Swiss Med Wkly. 2020 Dec 18;150:w20422. doi: 10.4414/smw.2020.20422. eCollection 2020 Dec 14.
Impact: 1.52 (2019)

Kessler C., **Gerber B**, Previdsomini M

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.

Blood

Impact: 17.543 (2019)

Nagler M, Asmis L, **Gerber B**, Ruosch S, Spirk D, Surbek D, Studt JD, Tsakiris D, Wuillemin WA

Venöse Thromboembolie in Gynäkologie und Geburtshilfe: Empfehlungen zum Management häufiger klinischer Situationen.

Schw Med Forum 2021

Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M^f, Bacher U, Bode P, Cavalli A, Condoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Gerull S, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Magini G, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pabst T, Pfister O, Planchette AL, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Treglia G, Tzankov A, Vetter F, Zweier M, Flammer AJ, **Gerber B**

Management of transthyretin amyloidosis: Guidelines from the 1st Swiss Amyloidosis Network (SAN) Consensus conference

Swiss Med Wkly. 2021

Impact: 1.52 (2019)

Wuillemin WA, **Gerber B**, Müller B, Pederiva S

Kommentare der Schweizer Expertengruppe zu den ASH-Guidelines 2021 zur Prophylaxe und Therapie von venösen Thromboembolien bei Tumorpatienten.

Schw Med Forum 2021